Day: 31 October 2021

The first bank to list on the ASX in 30 years has successfully made its journey to the milestone moment today. Judo Bank, also known as Judo Capital Holdings Ltd (ASX: JDO), has cemented itself in history on Monday as the small and medium-sized enterprise (SME) business bank made its debut in the public markets.

Around midday, shares in the freshest bank on the ASX are fetching a $2.16 price tag, up 2.86%. Miraculously, in the space of 5 years, Judo Bank has gone from a PowerPoint presentation to a more than $2.3 billion company in its current state.

Let’s put Judo under the microscope and get a sense of where it comes from and how it is different from the big four it hopes to challenge.

Judo Bank’s path to the ASX

Since its inception in October 2016, Judo Bank has been on a mission to serve SMEs and be the most trusted SME business bank in Australia. Those ambitions have been shared among an array of key people within the company, not the least of which include co-founders Joseph Healy and David Horney, among other former National Australia Bank Ltd. (ASX: NAB) executives.

Judo quickly gained its full banking licence in April 2019, less than three years after setting the wheels into motion. From there, the pace of growth has been exceptional, with the bank catering to SMEs that have been unable to secure lending through the traditional providers.

In turn, the loan book of Judo has flourished, surpassing $4.15 billion of aggregate funding to the SME sector as of 30 September 2021. The business bank experienced a 97% increase in its lending book during FY21 alone. Having grown up from its bootstrapping days, the management of Judo Bank felt it was time for it to join the big leagues on the ASX.

Getting set for the ASX involved Judo raising $657 million through its initial public offering (IPO). The raising attracted interest from a range of institutional and retail investors at an offer price of $2.10 per share. Incredibly, this implied a valuation of $2.3 billion after achieving ‘unicorn’ status only 18 months earlier.

As we now know, the $657 million capital raising was successful, along with Judo Bank’s ASX debut today.

How does is it different to the big four?

Judo Bank and its management pride themselves on doing banking “as it should be”, in the words of CEO Joseph Healy. This is a little ambiguous so let’s elaborate on what that means exactly.

The big bank contender has its sights set on the SME market. A place where management believes the big banks have neglected, with cookie-cutter financing and a high barrier to credit for many businesses, unless backed by some form of real estate as security.

Instead, the newest banking kid on the block wants to take a business-first approach. Essentially, dealing directly with SME customers with dedicated relationship managers to understand the business. By doing this, Judo can offer tailored financial solutions for its customers.

Since day one, Judo Bank’s purpose has been clear, to be Australia’s most trusted SME business bank by bringing back the craft of SME relationship banking.

Judo Bank Co-founder and CEO, Joseph Healy

Finally, the newly ASX-listed Judo Bank boasts a ‘legacy-free’ business model. Instead, opting for cloud-based technology to enable its relationship-centric lending model.

The post Judo Bank (ASX:JDO) hits the ASX, here’s how it differs from the big four appeared first on The Motley Fool Australia.

More reading

• Argosy (ASX:AGY) share price edges higher on Rincon update
• Advanced Human Imaging (ASX:AHI) share price sinks on US listing update
• Why Advanced Human Imaging, ResMed, Western Areas, and Westpac are falling
• Leading brokers name 3 ASX shares to buy today
• Why the Race Oncology (ASX:RAC) share price is up on Monday

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3wgbJPX

The Argosy Minerals Limited (ASX: AGY) share price is pushing higher on Monday. This comes after the company announced an operational update on construction works at the Rincon Lithium Project.

Argosy holds a 77.5% interest in the Rincon project, located in Salta Province, Argentina. The mine is situated within the ‘lithium triangle’ – the world’s dominant lithium production source.

During late afternoon trade, the lithium miner’s shares are up 1.72% to 29.5 cents. This means its shares have now risen more than 40% in the past month alone.

How is Argosy tracking at Rincon?

Investors are buying up Argosy shares following the company snapshot of its progress at the Rincon Lithium Project.

According to its update, Argosy stated that around 45% of the total works have now been completed to bring the Rincon Lithium Project online. The development of the modular 2,000tpa (tonnes per annum) of lithium carbonate production plant remains on schedule and on budget.

The company is aiming to achieve the first commercial production of lithium carbonate product from mid-2022.

Major construction works such as building the process plant, equipment and associated installations, and expansion of the brine system have all progressed. As such, Argosy provided a summary of the current progress:

• 99% of earthworks/land movements completed;
• 86% of site works completed (site camp/accommodation, laboratory, office, and other works);
• 73% of the brine system completed (pumping station and plant settling ponds);
• 32% of the process plant completed (plant equipment acquisition and plant warehouse);
• 33% of utilities and associated services (vapour system, communication system, and ancillary services) completed

Argosy stated that the construction phase is scheduled to be finished in April 2022. Other stages of the project, such as commissioning works, production test-works and ramp-up, are expected to follow.

What did the head of Argosy say?

Argosy managing director Jerko Zuvela touched on the update, saying:

The company’s Puna operations team continue making significant progress on construction and development works, toward commencing 2,000tpa lithium carbonate production operations at our Rincon Project. With lithium market sentiment and lithium carbonate prices maintaining strength, we are excited as we escalate works in transforming Argosy into a battery quality lithium carbonate producer and cashflow generator, and then to further progress the 10,000tpa project development expansion.

Argosy share price review

Since the beginning of the year, Argosy shares have zipped higher, recording gains of almost 270%. The company’s share price reached a 52-week high of 30.5 cents last week and could stretch further.

Argosy presides a market capitalisation of roughly $368.83 million with approximately 1.25 billion shares outstanding.

The post Argosy (ASX:AGY) share price edges higher on Rincon update appeared first on The Motley Fool Australia.

More reading

• Why ASX lithium shares are booming on Thursday
• ASX lithium shares lift as spot prices hit all-time highs

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3w6kD2m

The Advanced Human Imaging Ltd (ASX: AHI) share price is in negative territory during early afternoon trade. This comes after the company announced it has released a corporate presentation to raise money for its proposed listing on the tech-focused United States Nasdaq exchange.

At the time of writing, the human scanning technology provider’s shares are down 10.71% trading at $1.00.

ASX company eyes US entry

In today’s statement, Advanced Human Imaging advised it was gathering support for its US-based initial public offering (IPO).

The company received conditional approval from the Nasdaq to list its American depositary shares (ADS). However, it is not known yet how many shares in total will represent the number of ordinary shares already listed.

Based on a price range of US$7.00 to US$9.00, the company is looking to offer 1 ADS for every 9 ordinary Advanced Human Imaging shares. This is subject to market conditions and may change, including the size of the offer. The company is hoping to raise US$15 million from investors.

Maxim Group LLC has been appointed as the sole book-running manager, and will oversee the listing.

Advanced Human Imaging submitted an updated public filing the F-1 form to the Securities and Exchange Commission (SEC). The F-1 form is the registration required for foreign companies wanting to be listed on a United States stock exchange.

About the Advanced Human Imaging share price

The Advanced Human Imaging share price has fallen almost 20% in 2021 so far. When zooming out to the past 12 months, its shares have flatlined, down 2% for the period.

It’s a stark contrast to when the company’s shares were trading above the $2 mark during early March 2021.

Advanced Human Imaging has a market capitalisation of roughly $136.92 million, with approximately 136.92 million shares on issue.

The post Advanced Human Imaging (ASX:AHI) share price sinks on US listing update appeared first on The Motley Fool Australia.

More reading

• Why Advanced Human Imaging, ResMed, Western Areas, and Westpac are falling

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3jTXueo

The S&P/ASX 200 Index (ASX: XJO) has had a strong start the week. In afternoon trade, the benchmark index is up 0.55% to 7,363.4 points.

Four ASX shares that have failed to follow the market higher today are listed below. Here’s why they are falling:

Advanced Human Imaging Ltd (ASX: AHI)

The Advanced Human Imaging share price has tumbled 10% to $1.00. This morning the software company announced plans to raise US$15 million. The proceeds will be use research and development, business development, and marketing. The remainder of the proceeds will be used for general corporate purposes. This could include investing in or acquiring synergistic companies that are complementary to its technologies and working capital.

ResMed Inc. (ASX: RMD)

The ResMed share price is down 5% to $35.27. This decline appears to have been driven by a lukewarm response from brokers to last week’s quarterly update. This morning Macquarie retained its neutral rating and lifted its price target ever so slightly to $38.00. While it was pleased with its performance during the quarter, it feels its shares are close to full value now.

Western Areas Ltd (ASX: WSA)

The Western Areas share price is down almost 3% to $3.07. This morning the team at Citi reduced their FY 2022 earnings estimates for this nickel producer following its first quarter update. The broker has, however, held firm with its neutral rating and $3.40 price target.

Westpac Banking Corp (ASX: WBC)

The Westpac share price is down 6.5% to $24.01 following the release of its full year results. Although the banking giant doubled its cash earnings in FY 2021, this was still a touch short of expectations. In addition, a softening net interest margin and smaller than expected share buyback appear to be weighing on its shares. In respect to the latter, Australia’s oldest bank announced a $3.5 billion off-market share buyback. A note out of Morgans reveals that its analysts were forecasting a $5 billion buyback

The post Why Advanced Human Imaging, ResMed, Western Areas, and Westpac are falling appeared first on The Motley Fool Australia.

More reading

• Advanced Human Imaging (ASX:AHI) share price sinks on US listing update
• Leading brokers name 3 ASX shares to buy today
• The Resmed (ASX:RMD) share price is falling 5% on Monday. Here’s why
• Here’s everything to know about the Westpac (ASX:WBC) dividend after its earnings update
• ASX 200 (ASX:XJO) midday update: Westpac sinks, Macquarie raises $1.5bn

Motley Fool contributor James Mickleboro owns shares of Westpac Banking Corporation. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3ExRlwl

With so many shares to choose from on the ASX, it can be hard to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.

Three top ASX shares leading brokers have named as buys this week are listed below. Here’s why they are bullish on them:

Airtasker Ltd (ASX: ART)

According to a note out of Morgans, its analysts have retained their add rating but trimmed their price target slightly on this small jobs marketplace provider’s shares to $1.27. This follows the release of a resilient quarterly update last week. Morgans was pleased with the company’s performance given how over half its target market was locked down. The Airtasker share price is trading at $1.10 on Monday.

Macquarie Group Ltd (ASX: MQG)

A note out of Citi reveals that its analysts have upgraded this investment bank’s shares to a buy rating with an improved price target of $226.00. Citi was pleased with Macquarie’s performance in the first half and expects more of the same in the second half. Particularly given how the company is well-placed to benefit from the current energy crisis. Combined with upgraded guidance for commodities revenue and gain on sale revenue in MacCap, the broker has upgraded its earnings estimate for FY 2022 by 17% to $4,145 million. The Macquarie share price is fetching $197.00 today.

ResMed Inc. (ASX: RMD)

Another note out of Morgans reveals that its analysts have retained their add rating but trimmed their price target on this sleep treatment focused medical device company’s shares to $40.80. This follows the release of a better than expected first quarter update last week. While the broker acknowledges that supply constraints will limit market share gains from the rival product recall, it is still expecting solid earnings growth over the medium term. The ResMed share price is trading at $35.29 today.

The post Leading brokers name 3 ASX shares to buy today appeared first on The Motley Fool Australia.

More reading

• The Resmed (ASX:RMD) share price is falling 5% on Monday. Here’s why
• ASX 200 (ASX:XJO) midday update: Westpac sinks, Macquarie raises $1.5bn
• Can the Macquarie (ASX:MQG) share price break new highs over $200?
• Macquarie (ASX:MQG) share price falls after completing $1.5bn capital raising
• 5 things to watch on the ASX 200 on Monday

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Airtasker Limited and ResMed. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3jVAcVv

Shares in Australian pharmaceutical company Race Oncology Ltd (ASX: RAC) are up 4% from the open to now trade at $3.41 apiece. This follows an intraday high of $3.52.

Race Oncology shares are on the move despite there being no market-sensitive for the company today.

However, they are gaining ground amid a key update regarding a clinical trial submission the company announced today which is worth exploring at greater length.

Here are the details.

Race submits application to start phase 2 trial

The company advised that it has submitted the “first human ethics application to the Hunter New England Human Research Ethics Committee” for approval to commence a phase 2 trial with its drug candidate Zantrene.

Specifically, the application is to commence an open-label phase 2 clinical trial investigating Zantrene in two complex disease segments, Extramedullary Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndromes (MDS).

The former occurs when leukaemia spreads from the bone marrow and forms solid tumours in areas such as the skin, breast, kidney, or brain, etc.

The latter, MDS, is a category of blood cancers that affects the production of blood cells in bone marrow. Around a third of all patients with MDS diagnoses progress to develop AML, according to the company.

Being a phase 2 clinical trial, it will primarily examine the overall effectiveness and safety of Zantrene in patients with these conditions.

What does the trial look like?

The study, which Race labelled BISECT, will recruit up to 60 patients, separated into two ‘stratum’ or population groups.

Group 1 will receive a higher dose of Zantrene as a single treatment over 7 days with follow up cycles thereafter. The cohort will comprise patients with AML who can tolerate high-intensity chemotherapy.

The second group will receive Zantrene as a combination therapy, albeit at a lower dose, for patients who are unable to tolerate high-intensity chemo.

The trial is expected to take around 36 to 40 months to complete.

The application builds on previous studies indicating a potential therapeutic response in AML in combination with another drug, using mouse studies.

An important point for investors to note is that the trial “supports the use of orphan drug registration under the FDA 505(b)(2) pathway”.

The 502(b)(2) pathway in the US enables drug manufacturers to obtain Federal Drug Administration (FDA) approval without having to compile the mammoth amount of data that’s normally required with a new drug application (NDA).

If successful, this would remove much red tape for Race Oncology before commercialising Zantrene in the US.

What did management say?

Speaking on the announcement, Race Oncology’s CEO Phillip Lynch said:

This study supports our Pillar 3 registration ambition to see Zantrene’s historical safety and efficacy in AML demonstrated with superior drug combinations that may benefit patients who remain challenged by initial treatment failures. It is pleasing to be able to open up this trial to MDS patients who are equally in need of new improved treatment options.

Race Oncology share price snapshot

Race Oncology share price has climbed over 249% in the past 12 months after rallying 95% in the green since January 1.

That’s well ahead of the benchmark S&P/ASX 200 Index (ASX: XJO)’s return of about 25% in the past year.

The post Why the Race Oncology (ASX:RAC) share price is up on Monday appeared first on The Motley Fool Australia.

More reading

• Race Oncology (ASX:RAC) share price struggles despite new Leukemia study
• Race Oncology (ASX:RAC) share price edges higher amid patent update
• Why the Race Oncology (ASX:RAC) share price is storming higher today

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3CxrSm1

The Lynas Rare Earths Ltd (ASX: LYC) share price is currently up around 3% after the rare earth miner reconfirmed long-term support from a key stakeholder.

Lynas share price rises as letter signed

Lynas has signed a letter of agreement with Japan Australia Rare Earths (JARE), reconfirming JARE’s long-term support for the Lynas business.

What is JARE?

Lynas explained that JARE is a special purpose company established by Japan Oil, Gas and Metals National Corporation and Sojitz Corporation. Lynas and JARE are parties to a long-term senior loan facility, with a principal balance of US$145 million, an interest rate of 2.5% per annum and a maturity date of 30 June 2030. The company announced this loan facility in June 2019.

As agreed, Lynas and JARE continue to work together on the development of the Lynas business.

Further delay of interest payment

Lynas had previously announced that in support of Lynas’ capital expenditure on Lynas 2025 growth projects, JARE deferred interest of US$11.5 million until 31 October 2021, with no penalty and no additional interest. JARE has agreed to further defer the repayment of this interest until 31 March 2021, with no penalty and additional interest.

Quarterly update

It was just over a week ago that Lynas told investors how the first quarter of its 2022 financial year had gone compared to the fourth quarter of FY21.

Lynas said that its quarterly sales revenue was $121.6 million (down from $185.9 million in the FY21 fourth quarter) and the sales receipts were $92 million (down from $192 million).

Looking at the production, total rare earth oxide (REO) production was 3,166 tonnes (down from 3,778 tonnes), whilst neodymium and praseodymium (NdPr) production was 1,255 tonnes (a reduction from 1,393 tonnes.

However, Lynas noted that the rising COVID-19 cases in Malaysia meant that cracking and leaching plant was partially or fully shutdown for 11 days due to the unavailability of personnel who were required to isolate. Product finishing of non-NdPr products was also shutdown for 16 days during the period as it prioritised NdPr production with available personnel. The pandemic continued to affect logistics with delays in both inbound and outbound shipments affecting availability of key production inputs and finished product deliveries.

Despite those challenges, the team managed to maintain NdPr production at 70% of Lynas NEXT capacity.

The rare earth miner pointed out that demand for rare earth materials continues to be very strong in the magnet market and customers say that they expect this demand to further accelerate in 2022. The average China domestic price for NdPr was US$80.1 per kilo for the quarter.

Projects on track

Lynas also noted that work has continued with procurement and minor and preliminary works at the Kalgoorlie rare earths processing facility (as approved by the EPA) in March 2021. Concrete works were installed on the site to enable the delivery of the kiln shell, which is being shipped from Europe and is expected to arrive in WA in November 2021.

After the quarter finished, the WA EPA recommended the Kalgoorlie facility for environmental approval subject to conditions and released its assessment report on 20 October 2021.

Rating on the Lynas share price

The broker Ord Minnett currently rates Lynas as a sell with a price target of $4.30, which is approximately 40% lower than today’s price. Whilst Lynas is doing well in the current environment, the broker thinks the Lynas share price is valued too highly.

The post Here’s why the Lynas (ASX:LYC) share price is up 3% on Monday appeared first on The Motley Fool Australia.

More reading

• These were the best performing ASX 200 shares last week
• Can the Lynas (ASX:LYC) share price fall to $4 by the end of 2021?
• Why Aurizon, De Grey Mining, Lynas, and Yancoal shares are falling
• ASX 200 (ASX:XJO) midday update: BHP and Rio Tinto fall, Qantas higher
• Lynas (ASX:LYC) share price falls 7% on news of COVID-induced shutdown

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3kealIP

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a solid gain. At the time of writing, the benchmark index is up 0.8% to 7,382.5 points.

Four ASX shares that are climbing more than most today are listed below. Here’s why they are storming higher:

Ausnet Services Ltd (ASX: AST)

The Ausnet share price is up almost 4% to $2.57. The catalyst for this was news that the electricity distribution networks company has accepted a takeover offer from Brookfield Asset Management. According to the release, Brookfield has tabled a binding proposal of $2.65 per share, which is up from its original offer of $2.50 per share. As part of the terms of the agreement, Ausnet has terminated its due diligence process with APA Group (ASX: APA).

Charter Hall Group (ASX: CHC)

The Charter Hall share price is up over 4% to $18.07. Investors have been buying this property company’s shares after it upgraded its post-tax operating earnings per security (OEPS) guidance. Charter Hall now expects OEPS of no less than 83 cents per share in FY 2022, which represents a minimum 36% year on year growth rate.

Codan Limited (ASX: CDA)

The Codan share price is up 4.5% to $10.51. This gain appears to have been driven by bargain hunters swooping in after the metal detector company’s shares were sold off last week. The Codan share price sank 23% last week following the release of its annual general meeting update.

Imugene Limited (ASX: IMU)

The Imugene share price has jumped 7% to 53 cents. This morning Imugene announced a strategic collaboration with Eureka Therapeutics. The collaboration will evaluate Eureka’s anti-CD19 Artemis T-cell therapy in combination with Imugene’s CD19-expressing oncolytic virus onCARlytics in solid tumours. Eureka Therapeutics is a US based clinical-stage biotechnology company focused on developing novel cancer T-cell therapies to treat cancers.

The post Why Ausnet, Charter Hall, Codan, and Imugene shares are storming higher appeared first on The Motley Fool Australia.

More reading

• Why the Imugene (ASX:IMU) share price is up 9% on Monday
• ASX 200 (ASX:XJO) midday update: Westpac sinks, Macquarie raises $1.5bn
• Ausnet (ASX:AST) share price jumps as Brookfield offers $2.65/share
• These were the worst performing ASX 200 shares in October
• These were the worst performing ASX 200 shares last week

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3brlHnN

Shares in global medical device company Resmed Inc (ASX: RMD) are sliding in early afternoon trade today as the US-based entity released its Q1 FY22 earnings.

At the time of writing, Resmed shares are 5.27% into the red, sinking to $35.21 apiece.

Resmed share price slides despite 20% revenue growth in Q1

During the quarter, Resmed achieved a number of investment highlights, including:

• Revenue of US$904 million, a 20% year on year (YoY) growth pattern
• Gross margin of 56%, down from 57.2% year on year
• Income from operations increased by 21% from the same time last year to US$261.9 million
• Operating profit gained 18% from the year prior with net income up 14% YoY to US$203.6 million
• Diluted earnings per share of US$1.39, up from US$1.22 during the same period in FY21
• Declared quarterly cash dividend of US42 cents per share

What happened this quarter for Resmed?

The company announced its quarterly earnings update with the release of its 10-K form. This is the standard documentation required by US-listed or domiciled companies when reporting earnings.

Resmed came in with a quarter that was ahead of analyst expectations, exhibiting a period of decent growth throughout its income statement.

For instance, revenue grew by 20% YoY to US$904 million, around $46 million above the consensus of analyst estimates for its Q1 sales.

Yet, despite the growth, the company’s gross margins contracted by around 270 basis points to 56%. This was the result of higher shipping and manufacturing costs across the board during calendar year 2021 to date.

Geographically speaking, revenue growth in Europe and Asia was strongest for the company in Q1 with an average of 21% growth in gross earnings in these regions.

This carried vertically down the income statement for Resmed. Its income from operations also expanded by 21% YoY and net income gained 14% during the quarter (20% on non-GAAP accounting figures).

Operating profit also rose around 20% for the quarter when compared to Q1 FY21. However, it was impacted by a payment made to the Australian Tax Office (ATO) of US$284.8 million.

According to its earnings report, this was actually the settlement amount of US$381.7 million net of prior remittances for all prior years since 2009.

As a result of its earnings strength this quarter, the board declared its quarterly cash dividend of US42 cents per share, payable on 16 December 2021.

Although this is in US currency, Australian holders of Resmed’s ASX-listed shares will receive the equivalent in Aussie dollars with an ex-dividend date of 10 November.

What did management say?

Speaking on the announcement, Resmed CEO Mick Farrell said:

Our first-quarter results demonstrate strong performance across our business with double-digit growth in both top-line and bottom-line metrics, driven by ongoing high demand for our sleep and respiratory care products, and steady growth across our software-as-a-service business.

He added:

It is through the extraordinary efforts of our global ResMed team that we were able to deliver products and solutions to our customers amid unprecedented supply chain challenges that continue to restrict access to critical electronic components.

What’s next for Resmed?

Resmed has previously stated a full-year revenue outlook of US$300 million to $350 million.

However, it also concurrently stated on its earnings call that it does not generally give specific ‘quantitative’ guidance.

When probed by analysts, the company reiterated its US$300–$350 million figure without going into too much detail.

Overall, it’s been a choppy year for Resmed shareholders who have still enjoyed a share price increase of 30% since January 1.

Over the last 12 months, the Resmed share price has climbed 26% into the green, roughly in line with the benchmark S&P/ASX 200 Index (ASX: XJO)’s gain of just under 25% in that time.

The post The Resmed (ASX:RMD) share price is falling 5% on Monday. Here’s why appeared first on The Motley Fool Australia.

More reading

• Why HT&E, JB Hi-Fi, Reece, and ResMed shares are charging higher
• ASX 200 (ASX:XJO) midday update: Macquarie doubles profit, ResMed jumps
• ResMed (ASX:RMD) share price jumps 7% on Q1 earnings beat
• 5 things to watch on the ASX 200 on Friday
• 3 buy-rated ASX shares

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3mvA28Y

Shares in biotech company Imugene Limited (ASX: IMU) are lifting in afternoon trade today and are changing hands 9.09% higher at 54 cents.

Imugene’s share price has been gaining ground today after the company announced a strategic partnership with Eureka Therapeutics, Inc.

Here are the details.

What did Imugene announce today?

Imugene gave in-depth coverage of its strategic partnership with clinical stage biotechnology Eureka Therapeutics, including an investor presentation of the data and collaboration itself.

The collaboration will “explore the therapeutic potential of a combination of Imugene’s CD19 oncolytic virus onCARlytics in combination with Eureka’s anti-CD19 ARTEMIS T-cell therapy for the treatment of solid tumours”.

For reference, Imugene has a novel hypothesis that it uses to treat solid tumours using its onCARlytics platform, by priming tumour cells for destruction with a tumour marker called CD19.

Imugene states that Eureka’s T-Cell therapy may be superior to CAR-T cells – a kind of bio-engineered T-Cell designed to specifically attack cancer cells, that Imugene is currently studying.

It reckons that based on head-to-head preclinical trials, Eureka’s ARTEMIS T-Cell therapy may be a better fit as a combination therapy with onCARlytics instead of CAR-T therapy, in order to eradicate solid tumours in eligible patient groups.

This is because ARTEMIS T Cells “demonstrated superior efficacy, enhanced tumour infiltration, and less T-cell exhaustion” in the aforementioned studies.

Eureka already has a number of clinical partnerships on its books with the likes of French biopharma company Sanofi S.A, and oncology giant Lyell Immunopharma Inc (NASDAQ: LYEL).

In fact, it has also eclipsed the top 10 mark in terms of the world’s best ‘CAR-T Patent Assignees Worldwide’ with its ARTEMIS asset in 2020, per the release.

News of the collaboration sent Imugene’s share price higher, and today’s trading volume is already 122% of its 4-week average after just a few hours of activity.

What did management say?

Speaking on the announcement, Imugene’s CEO Leslie Chong said:

T-cell and CAR-T therapies have not achieved much success in solid tumours in part because of a lack of tumour specific targets. By using our proprietary oncolytic technology to force the tumour to express the CD19 target, we now have the ability to address this shortcoming. We believe the synergy between our onCARlytics platform and Eureka’s anti-CD19 ARTEMIS T-cells has the potential to shift the cellular medicine paradigm in treating solid tumours.

Imugene share price snapshot

It’s been a terrific year for Imugene and its share price, having posted an outsized return of 440% this year to date.

This extends its run into the green to over 800% in the past 12 months, a galaxy away from the benchmark S&P/ASX 200 index (ASX: XJO)’s gain of around 25% in the same time.

The post Why the Imugene (ASX:IMU) share price is up 9% on Monday appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX shares today
• Here are the top 10 ASX shares today
• Which ASX 300 shares are the biggest winners and losers on Tuesday?
• Why is the Imugene (ASX:IMU) share price lifting 7% today?
• These were the best performing ASX biotech shares in September

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3mtMfey